Company Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.
The company’s lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell atopic dermatitis, asthma, psoriasis, and fibrotic diseases.
It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer.
It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab.
Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
| Country | United States |
| Founded | 2014 |
| IPO Date | Mar 23, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Richard Miller |
Contact Details
Address: 901 Gateway Boulevard, Third Floor South San Francisco, California 94080 United States | |
| Phone | 650 900 4520 |
| Website | corvuspharma.com |
Stock Details
| Ticker Symbol | CRVS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001626971 |
| CUSIP Number | 221015100 |
| ISIN Number | US2210151005 |
| Employer ID | 46-4670809 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard A. Miller M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder and Independent Director |
| Leiv Lea | Chief Financial Officer |
| Dr. William Benton Jones Ph.D. | Senior Vice President of Pharmaceutical Development |
| Jeffrey S. Arcara | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |